GIST
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Novartis breaks ground on US radioligand therapy site
The construction is part of the company’s investment in US research and manufacturing
Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Scotland becomes first part of UK to screen all newborn babies for SMA
The screening is part of a two-year evaluation funded by the Scottish government and Novartis
Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment
The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study